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Abstract: Pseudomonas aeruginosa is an opportunistic pathogen that predominates during the 
later stages of cystic fibrosis (CF) lung infections. Over many years of chronic lung colonization, 
P. aeruginosa undergoes extensive adaptation to the lung environment, evolving both toward a 
persistent, low virulence state and simultaneously diversifying to produce a number of pheno-
typically distinct morphs. These lung-adapted P. aeruginosa strains include the small colony 
variants (SCVs), small, autoaggregative isolates that show enhanced biofilm formation, strong 
attachment to surfaces, and increased production of exopolysaccharides. Their appearance in 
the sputum of CF patients correlates with increased resistance to antibiotics, poor lung func-
tion, and prolonged persistence of infection, increasing their relevance as a subject for clinical 
investigation. The evolution of SCVs in the CF lung is associated with overproduction of the 
ubiquitous bacterial signaling molecule cyclic-di-GMP, with increased cyclic-di-GMP levels 
shown to be responsible for the SCV phenotype in a number of different CF lung isolates. Here, 
we review the current state of research in clinical P. aeruginosa SCVs. We will discuss the 
phenotypic characteristics underpinning the SCV morphotype, the clinical implications of lung 
colonization with SCVs, and the molecular basis and clinical evolution of the SCV phenotype 
in the CF lung environment.
Keywords: small colony variants, cystic fibrosis, cyclic-di-GMP, Pseudomonas aeruginosa, 
RsmA, antibiotics
Introduction
Cystic fibrosis (CF) is a recessively inherited genetic disease in which the cystic fibro-
sis transmembrane conductance regulator (CFTR) gene is mutated, leading either to 
partial or complete loss-of-function. CFTR encodes a chloride ion channel, and the 
loss of ion transport across epithelial cell membranes leads to osmotic imbalance, and 
consequently to the buildup of sticky mucus in the lower respiratory tract.1 CF lungs 
are highly prone to microbial infection, with chronic infection beginning in infancy 
for the overwhelming majority of cases and continuing throughout the patient’s life. 
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen and the predomi-
nant infective species isolated from late-stage CF lung infections.2,3 Once established in 
the lungs of CF patients, P. aeruginosa infections are extremely difficult to completely 
eradicate, and the aggravation and progressive tissue degradation associated with 
repeated infectious relapses lead to morbidity and eventually death.3 P. aeruginosa 
lung infections typically progress clonally from infection with a single environmentally 
acquired genotype4,5 and, over the course of long-term chronic CF infections, undergo 
extensive genetic and phenotypic adaptation to the lung environment.6,7
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There are two main consequences of this adaptation: 
first, the progressive transition toward a persistent, low 
virulence state, and second, a related diversification into a 
number of different phenotypes.6,7 These include mucoid 
cells, which overproduce alginate and form distinc-
tive slimy colonies,8 and small colony variants (SCVs, 
Figure 1), which are typically slow-growing isolates that 
show strong attachment to surfaces, autoaggregation, 
enhanced exopolysaccharide production, and biof ilm 
formation.9,10 In recent years, several studies have estab-
lished a causal link between P. aeruginosa SCVs and 
persistence of infection in animal models,11–13 supporting 
the hypothesis that the SCV phenotype confers a fitness 
advantage under chronic infection conditions, and thus 
plays an important role in the pathogenesis of P. aeruginosa 
lung infections. P. aeruginosa SCVs also emerge in other 
situations that favor chronic infections, including in 
mechanically ventilated patients or in those suffering from 
chronic obstructive pulmonary disease.14,15 These studies 
suggest that persistent P. aeruginosa morphotypes such 
as SCV represent genetic adaptations to the hostile milieu 
in the patient, with characteristics including resistance to 
phagocytosis,12 antimicrobial resistance due to slow growth 
or increased persister cell populations,16,17 and reduced 
virulence18 potentially contributing to selection.
In this review, we will summarize the current state of 
research into clinical P. aeruginosa SCVs. We will discuss 
the initial discovery and characterization of SCVs in the spu-
tum of CF patients, the phenotypic characteristics associated 
with the SCV morphotype, and the clinical implications of 
lung colonization with SCVs. Finally, we will address the 
molecular basis of the SCV phenotype and possible evolu-
tionary routes to SCV generation, with an emphasis on SCV 
evolution in the lung environment.
Discovery and initial 
characterization of SCVs  
in the CF lung
Phenotypic variation between different P. aeruginosa isolates 
in CF sputum has been recognized for many years. While the 
alginate-overproducing mucoid phenotype8 has until recently 
garnered the most attention, it has long been recognized that 
SCVs (previously known as dwarf colonies) also arise in the 
chronically infected respiratory tract of CF patients.19 For 
example, Thomassen et al20 examined P. aeruginosa isolates 
from 286 CF patients over a 3-month period in 1976–1977 
and determined the frequency and distribution of different 
morphotypes. In this study, dwarf colonies were identified in 
the sputum of 14% of patients, although these colonies were 
always found in conjunction with other morphotypes.20 The 
first clinical study to specifically focus on the distribution 
and phenotypic characteristics of P. aeruginosa SCV iso-
lates from CF patients took place in Germany from 1996 to 
1998. Häussler et al17 tested the sputum of 86 CF patients for 
P. aeruginosa SCVs, identifying them in 33 patients. Over the 
course of this study, around 3.0% of the total P. aeruginosa 
isolates collected were classed as SCVs. These colonies were 
characterized as small (1–3 mm in diameter), slow growing, 
and more resistant to several different classes of antibiotics 
than subsequent planktonic revertants.17 Häussler et al17 went 
on to characterize some of their SCV isolates, reporting 
that these strains were hyperpiliated and autoaggregative. 
The SCV morphs tested showed increased twitching motil-
ity and a marked ability to form biofilms and to attach to 
human pneumocytes.10 Simultaneously with these clinical 
SCV studies, the molecular biology of SCV formation was 
being investigated by two independent groups. Drenkard 
and Ausubel21 showed that P. aeruginosa SCV formation 
could be induced under laboratory conditions by the addi-
tion of kanamycin and linked this phenotype to the putative 
cyclic-di-GMP (cdG) phosphodiesterase gene pvrR. At the 
same time, D’Argenio et al22 identified the WspR diguanylate 
cyclase (DGC) and showed that it was responsible for SCV 
formation in the laboratory strain PA01.
Phenotypic characteristics of the 
SCV morphotype
In agreement with the early clinical research, clinical and 
laboratory-derived SCVs generally display increased resis-
tance to a broad range of antibiotics.17,21,23 Exposure to subin-
hibitory antibiotic concentrations has been shown to induce 
attachment and SCV formation in vitro, possibly as part of 
Figure 1 The Pseudomonas aeruginosa SCv phenotype.
Notes: Photographs of P. aeruginosa strains grown on LB agar containing 0.004% 
Congo Red dye for 24 hours at 37°C. (A) wild-type P. aeruginosa PA01 forms flat, 
slightly wrinkled colonies. (B) The SCV strain ∆yfiR12 forms small, rugose colonies 
that adhere strongly to surfaces and bind tightly to Congo Red. Photographs 
courtesy of Sebastian Pfeilmeier.
Abbreviations: LB, Lysogenic broth; SCV, small colony variant.
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a defense response.21,24 SCVs are also usually nonmotile, 
with flagellar motility absent in most SCVs characterized to 
date.12,23,25 Hyperpiliation has been reported for some strains, 
with these isolates displaying increased twitching motility 
as a result,10 although the distribution of this phenotype is 
unknown. Probably the most prominent phenotype associ-
ated with SCV formation is the significantly enhanced pro-
duction of one or more exopolysaccharide molecules.9,12,25 
P. aeruginosa produces at least three exopolysaccharides. 
The most noticeable of these in clinical CF isolates is 
alginate, the overproduction of which produces the slimy, 
mucoid phenotype.8 The role of alginate in SCV formation 
is unclear, although SCV strains have been identified that 
overproduce this molecule.26 Also produced are the glucose-
rich exopolysaccharide Pel, and Psl, which contains glucose, 
mannose, and rhamnose.27 Both Pel and Psl overproduction 
have been explicitly linked to SCV formation, and deletion 
of both pel and psl operons reverts an SCV to a smooth 
phenotype.12,25 Many of the other phenotypes associated with 
SCV, including their enhanced biofilm formation and surface 
attachment,10 small size (stemming from autoaggregation),17 
resistance to phagocytosis,12 and infectious persistence,11–13 
have been linked to exopolysaccharide overproduction in 
these morphs.
A striking characteristic of P. aeruginosa in the CF 
lung is its extraordinary degree of phenotypic diversity. For 
example, based on a year-long study of sputum samples from 
ten CF patients infected with the same initial P. aeruginosa 
strain, Mowat et al28 examined the phenotypic charac-
teristics of 1,720 individual isolates. The P. aeruginosa 
populations in each individual sputum sample in this study 
showed extensive phenotypic diversity, with the majority 
of diversity occurring within sputum samples rather than 
between patients. In agreement with this, Workentine et al29 
examined a more extensive series of phenotypes for 169 
clonal isolates from a single chronically colonized patient. 
Once again, the researchers observed a very high degree 
of phenotypic variation. Interestingly, every isolate in this 
study presented a different phenotypic profile from the oth-
ers, with very little correlation seen between the majority of 
tested phenotypes.29
The implications of these findings for SCVs in the 
lung environment are that apart from the core phenotypic 
characteristics by which SCVs are identified in the clinic, 
a high degree of variation might be expected for every other 
phenotype. Examination of the phenotypes of clinical SCVs 
has largely confirmed this hypothesis. For example, Häussler 
et al17 reported reduced growth rates for their clinical SCV 
isolates, an observation that has since been repeated for other 
SCV genotypes growing in liquid media.23 However, work 
from other researchers has shown that this does not apply to 
all strains or under all growth conditions.30 Similarly, sidero-
phore production has been reported as being downregulated 
in some SCVs,30 but as being upregulated in others.12,23,31 
Cytotoxicity/virulence is another potentially plastic phe-
notype in SCVs. Long-term lung colonization is generally 
associated with a loss of cytotoxicity, and downregulation of 
the type III secretion system (T3SS).32 Reduced cytotoxicity 
is a recognized characteristic of rsmA- strains,13 which form 
SCVs under laboratory conditions.33 However, a transcrip-
tional analysis of the well-studied strain SCV20265 showed 
significant upregulation of T3SS genes compared to its clonal 
predecessor.31 This increased expression agreed with the 
results of an earlier proteomic analysis of the same strain34 
and corresponded to significantly increased cytotoxicity in 
a murine infection model.31 Given that SCVs generally arise 
after significant periods of lung colonization, many of the 
phenotypes associated with long-term, chronic lung infection 
(loss of virulence, reduced quorum sensing, hypermutability, 
etc18,23,35–37) might be expected to correlate with SCV. How-
ever, as the studies above indicate, many exceptions exist, 
and phenotypic variation between SCV morphotypes is likely 
to be extensive.28,29
The clinical implications of SCV 
lung infection
At least two independent reports have identified a strong 
relationship between the presence of SCVs in the CF lung 
and poor clinical outcomes. The 1999 Häussler et al17 study 
of SCVs in CF sputum examined a total of 86 patients with 
chronic P. aeruginosa lung infections. While only 3% of all 
colonies recovered during the study were classed as SCVs, 
those patients from whom SCVs were isolated (33 out of 86) 
displayed poorer lung function than those who did not dis-
play SCV colonization. The forced expiratory volume in the 
first second (FEV
1
) score for these patients was 56%, which 
was significantly lower than the FEV
1
 of SCV-negative 
patients (80%). More recently, Schneider et al38 looked for 
P. aeruginosa and Staphylococcus aureus SCVs in sputum 
samples from 98 CF patients. Over a 3-month period, 9.2% 
of patients in this study were colonized with P. aeruginosa 
SCVs.38 In agreement with the findings of Häussler et al,17 
patients having SCVs had poorer lung function, with lower 
blood oxygen levels and a significantly lower FEV
1
 score 
(39%) than the non-SCV patients (65.5%). The body mass 
of SCV-colonized patients was also significantly lower 
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(mean 14.0% underweight compared with 2.7% for non-
SCV patients).38
While it is difficult to confidently infer a causal relation-
ship between the SCV phenotype and poor clinical prognosis 
based on correlation studies alone, there is substantial evi-
dence supporting a role for SCVs in persistence in a clinical 
setting. Three independent research groups, using different 
animal infection models and genetically distinct SCV strains, 
have established causal relationships between the SCV phe-
notype and persistence of infection.11–13 Furthermore, many of 
the phenotypes associated with SCV have been directly linked 
to advantageous survival traits during chronic infection. For 
example, Malone et al12 showed that extracellular polysac-
charides (EPS) overproduction rendered P. aeruginosa SCVs 
highly resistant to macrophage phagocytosis. As mentioned 
previously, SCVs generally show enhanced antibiotic resis-
tance compared to wild-type P. aeruginosa.17,21,23 While 
a causal relationship again remains to be established, this 
antibiotic resistance may contribute to SCV survival in the 
CF lung during antibiotic chemotherapy.
Fully defining the relationship between SCVs and per-
sistence in the CF lung is likely to remain a challenge for 
the foreseeable future. While correlations between clinical 
SCV colonization and poor lung function are clear, and SCVs 
contribute to infectious persistence in laboratory and animal 
studies, it is currently unknown whether SCVs trigger poor 
clinical outcomes or just preferentially associate with deterio-
rating lungs. Short of invasive or postmortem investigations 
of CF lungs, an interesting recent advance that may provide 
an answer is the ex vivo porcine lung model developed by 
Harrison et al.39 This system has been successfully tested 
with P. aeruginosa quorum sensing mutants and promises 
to shed further light onto microbial colonization of the lung 
environment.
The molecular bases of the SCV 
phenotype: cyclic-di-GMP and the 
GacAS/RsmAZY pathway
Following early indications from two independent research 
labs,21,22 strong evidence has accumulated for a causal 
link between the SCV phenotype and the bacterial sec-
ond messenger cdG.12,25,40–42 cdG is a ubiquitous bacterial 
signaling molecule that controls a wide range of cellular 
processes involved in the transition between motile, viru-
lent, and sessile biofilm forming lifestyles.43,44 The cyclic 
dinucleotide is produced from two molecules of GTP 
(guanosine triphosphate) by DGCs and degraded to pGpG 
(5′-phosphoguanylyl-(3′-5′)-guanosineguanosine) by 
 phosphodiesterases;45 enzymes containing the conserved 
GGDEF and EAL/HD-GYP domains, respectively.46–49 In 
general, cdG production is associated with community 
behavior phenotypes such as EPS production and biofilm 
formation, while low cdG levels lead to enhanced motility, 
virulence, and a single-celled lifestyle43 (Figure 2). cdG sig-
nal transduction is a highly complex process, with many bac-
terial species containing dozens of different cdG-signaling 
proteins.43 P. aeruginosa is no exception, with 33 predicted 
GGDEF and 17 EAL domain-containing proteins.50,51 These 
cdG metabolic enzymes control the intracellular level of cdG 
and hence regulate the expression of various phenotypic 
outputs. In P. aeruginosa, this includes exopolysaccharide 
production,52–54 production and deployment of proteina-
ceous adhesins,55,56 siderophore production,12 rhamnolipid 
biosynthesis,57 and virulence and cytotoxicity systems,51,58–60 
as well as the assembly, function, and control of type IV 
pili61,62 and the bacterial flagellum.54,63–65
cdG affects cell behavior by controlling phenotypic out-
puts at every regulatory level, from gene expression through 
to allosteric modulation of phenotypic outputs.43 These effects 
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Figure 2 cdG signaling.
Notes: cdG is produced from GTP by GGDEF proteins and degraded by EAL 
and HD-GYP phosphodiesterases. cdG binds to a variety of different receptors, 
suppressing motility and virulence and promoting EPS production, biofilm formation, 
and the SCv phenotype.
Abbreviations: cdG, cyclic-di-GMP; EPS, extracellular polysaccharides; GTP, 
guanosine triphosphate; pGpG, 5′-phosphoguanylyl-(3′-5′)-guanosineguanosine; 
SCv, small colony variant.
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occur through binding to specific effector proteins, whose 
activity is altered upon interaction with cdG. Consistent 
with the high complexity of cdG signal transduction, bind-
ing is highly promiscuous and occurs with a wide range of 
different protein folds.66,67 For example, the PilZ domain is a 
dedicated cdG binding protein, with examples like Alg44 in 
P. aeruginosa, which is a regulator of alginate biosynthesis.52 
Furthermore, not all GGDEF, HD-GYP, and EAL domain 
proteins have cdG metabolic activity. A substantial minority 
have degenerate active sites and instead function by bind-
ing cdG, via protein–protein interactions or through other 
alternative mechanisms.66,67 For example, the P. aeruginosa 
EPS synthase component PelD binds to cdG, at a conserved 
site on its degenerate GGDEF domain, and induces a confor-
mational change in the Pel synthase machinery that leads to 
activation and EPS production.68 cdG also binds to a number 
of different transcriptional regulators. In P. aeruginosa, this 
includes the flagellar and EPS-gene master regulator FleQ, 
which controls pel and psl EPS operon transcription.54,69 The 
metabolism of cdG is under extensive spatial and temporal 
control in P. aeruginosa. Expression and translation of cdG 
genes is regulated by various cellular inputs, including sigma 
factors, cell cycle control, quorum sensing, and translational 
regulation.43,60,70 A further, significant level of control exists 
at the posttranslational level, with the majority of GGDEF, 
EAL, and HD-GYP domain proteins also containing diverse 
sensory inputs, including PAS, GAF, and response-regulator 
receiver domains.43
The role of cdG in P. aeruginosa SCV formation is now 
well-established. For example, a strong SCV phenotype can 
be triggered under laboratory conditions by overexpressing a 
DGC gene in trans,44 a phenotype that can be reversed by dis-
rupting the pel and psl EPS synthase operons (Figure 3).12 The 
intracellular level of cdG has been shown to be elevated in sev-
eral clinical and laboratory-derived SCVs.12,25,42 Furthermore, 
mutations in several P. aeruginosa cdG signaling pathways 
have been shown to induce SCV phenotypes in vitro. In each 
case, elevated intracellular levels of cdG have been linked to 
overproduction of either exopolysaccharides9,25,41 or fimbrial 
adhesins,40,71 and consequently to SCV formation.
As well as cdG signaling pathways, other genetic loci 
have been implicated in persistence of infection and/or SCV 
formation in P. aeruginosa. A prominent example is the 
GacAS/RsmAZY signaling system (Figure 4), an important 
regulator of the switch between chronic and acute infectious 
lifestyles in many Gram-negative bacterial species, including 
P. aeruginosa.70,72 RsmA is a small, translational regulator that 
specifically recognizes and binds to GGA sequences in the 5′ 
leader region of target mRNAs. RsmA reciprocally controls 
the translation of mRNAs associated with Type III/Type VI 
secretion and Psl exopolysaccharide synthesis,33,70 leading 
to the suppression of biofilm-associated phenotypes and 
promoting secondary metabolism, motility, and virulence. 
Figure 3 cdG and EPS define the SCV phenotype.
Notes: Photographs of Pseudomonas aeruginosa strains grown on LB agar for 24 hours 
at 37°C. (A) Overexpression of the DGC gene wspR induces the SCv phenotype 
in P. aeruginosa PA01. This phenotype is dependent on the presence of intact ePS 
operons. (B) Overexpression of wspR in a pel/psl- mutant still leads to alterations in 
colony morphology, but the distinctive small, rugose SCV phenotype is abolished. 
Photographs courtesy of Sebastian Pfeilmeier.
Abbreviations: cdG, cyclic-di-GMP; EPS, extracellular polysaccharides; SCV, small 
colony variant; LB, Lysogenic broth; DGC, diguanylate cyclase; WT, wild-type.
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Figure 4 The GacAS/RsmAZY signaling network.
Notes: GacAS-mediated expression of the sRNAs, RsmZ and RsmY, inactivates 
RsmA, leading to increased translation of target mRNAs, including for the Psl 
EPS pathway. GacS activity is controlled in turn by the hybrid TCS proteins LadA 
and RetS.
Abbreviations: ePS, extracellular polysaccharides; TCS, two-component signal.
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Deletion of the rsmA gene in P. aeruginosa PA01 induces an 
SCV phenotype as a consequence of increased psl mRNA 
translation,33 and has been shown to increase infectious per-
sistence in a murine lung model.13
In Pseudomonas spp. the activity of RsmA is con-
trolled by the GacAS two-component signal transduction 
system. GacS is a transmembrane histidine protein kinase 
and activates its cognate response regulator GacA by 
phosphotransfer. Phosphorylated GacA promotes transcrip-
tion of the antagonistic sRNAs, RsmY and RsmZ.73 RsmY/
RsmZ contain multiple GGA trinucleotides in the exposed 
stem-loops of their predicted secondary structures and 
inhibit RsmA activity by competing for RsmA binding, 
thus titrating the translational regulator away from its target 
mRNAs (Figure 4). The GacAS system is itself controlled 
by the two-component signal hybrid proteins LadS and RetS. 
RetS is an antagonist of GacS activity, and thus suppresses 
RsmZ/Y levels. Rather than operating via a conventional 
histidine protein kinase phosphotransfer mechanism, RetS 
forms heterodimers with GacS, and thus blocks GacS auto-
phosphorylation phosphotransfer to GacA.74 The LadS pro-
tein positively controls rsmZ/Y expression, and thus works 
to suppress RsmA activity. Although the mechanism of 
LadS function is currently uncharacterized, it may work by 
counteracting RetS activity (Figure 4).72 Signal transduction 
through the Gac/Rsm pathway is highly complex, and affects 
the production of dozens of different proteins.70 In addition 
to direct RsmA translational regulation, the Gac/Rsm system 
indirectly affects numerous additional cellular behaviors via 
the regulation of signaling pathways, including both cdG 
metabolism and quorum sensing.60,70 Similar to cdG, muta-
tions in quorum sensing genes are strongly associated with 
persistence during chronic CF lung infections.6,75
Evolution of SCVs in the CF lung
Having colonized the respiratory passage and lungs of a 
CF patient, in most cases, a P. aeruginosa infection persists 
throughout the patient’s lifetime. Patients are typically 
colonized by a single environmentally acquired genotype4,5 
(although some genotypes such as the Liverpool epidemic 
strain are infectious and can be transmitted from patient 
to patient76). P. aeruginosa CF lung infections generally 
alternate between periods of chronic, largely asymptom-
atic colonization and relapses into aggravated infection.1 
Over several years, the progressive tissue degradation that 
accompanies these repeated infectious relapses leads to lung 
failure and premature death.3 As stated above, P. aeruginosa 
strains undergo extensive adaptation to the lung  environment 
throughout the period of chronic lung infection,6,7 with 
multiple distinct phenotypes including SCVs arising in the 
lung population.7,10,77 Despite generally originating from a 
single clonal genotype, significant genetic variation exists 
between individual sputum isolates sampled at any one 
time,28,29 providing an explanation for the long-observed 
phenotypic heterogeneity in CF P. aeruginosa isolates.19,20
Perhaps unsurprisingly, the most commonly identified 
SCV-inducing mutations are loss-of-function mutations in 
repressor proteins that control the activity of DGCs (Table 1). 
A well-studied example is the Wsp pathway,41 which contains 
a methyl-accepting chemotaxis receptor (WspA) and a DGC 
response regulator (WspR). WspR overproduction/activation 
induces an SCV phenotype,22,41 displaying strong attachment 
and increased expression of the pel and psl exopolysaccharide 
operons. Under laboratory conditions, the principle route to 
SCV evolution is via loss-of-function mutations in the methyl-
esterase gene wspF.25,41 Without WspF, WspA and hence WspR 
are constitutively activated, leading to cdG synthesis and SCV 
Table 1 Mutational targets for Pseudomonas aeruginosa SCv 
formation
Gene Protein  
function
Notes Reference
yfiN DGC Constitutively active  
mutants isolated from  
the CF lung
Malone et al26
yfiR YfiN repressor  
protein
Putative loss-of-function  
mutants isolated from  
CF lung
Malone et al26
wspF Methylesterase Loss-of-function leads  
to activation of wspR  
DGC. Mutants identified  
in CF sputum isolates
Smith et al,6 
Blanka et al42
fleQ Transcriptional  
regulator of pel  
and psl ePS loci
Mutation leads to SCV  
phenotype in vitro  
Mutants identified in CF  
sputum isolates
Smith et al6
accBC Fatty acid  
biosynthesis  
operon
Upstream mutation  
stabilizes accBC mRNA,  
modifying plasma  
membrane and triggering  
WspR DGC activation
Blanka et al42
mutS Mismatch repair  
system
Mutations arise with  
high frequency in CF  
lungs. Associated with  
persistence, chronic  
lifestyles, and SCv  
formation
Mena et al,35 
Oliver et al,37 
Hogardt et al79
rsmA Translational  
regulator of  
chronic lifestyle  
switch
Mutation leads to SCV  
phenotype in vitro,  
possibly mutS associated?
Irie et al33
Abbreviations: SCV, small colony variant; DGC, diguanylate cyclase; CF, cystic 
fibrosis; EPS, extracellular polysaccharides.
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formation through EPS overproduction (Figure 5).41,78 There 
is evidence that wspF loss-of-function also represents a route 
to clinical SCV evolution. In 2006, Smith et al6 carried out 
a longitudinal study of lung-adapted P. aeruginosa isolates 
and identified several different backgrounds in which the 
wspF gene was mutated. This study also identified a number 
of mutations in the transcriptional regulator fleQ. Deletion 
of fleQ induces an autoaggregative phenotype in PA01, with 
many of the characteristics of SCV colonies.54 While the mor-
phologies of the lung isolates in the Smith et al6 study were 
not characterized in detail, these data nonetheless implicate 
both wspF and fleQ as potential mutagenic targets for SCV 
generation in the CF lung (Figure 5).
Blanka et al42 recently identified an interesting addi-
tional mechanism for SCV evolution in the CF lung isolate 
SCV20265. Comparison of the SCV20265 genome with 
those of several laboratory-derived revertants identified a 
causal mutation for the SCV20265 aggregative phenotype. 
This study showed that a point mutation in the 5′ untrans-
lated region of accBC, a gene cluster responsible for fatty 
acid biosynthesis, leads to mRNA stabilization and a con-
sequent increase in the proportion of short-chain fatty acids 
in the plasma membrane. In turn, this change in membrane 
composition triggered activation of the Wsp system and 
cdG overproduction via WspR.42 Intriguingly, the genome 
of SCV20265 was also shown to contain a second, additive 
mutation in the methylesterase gene wspF, shown in previ-
ous studies to induce an SCV phenotype.6,25 These findings 
suggest that both regulatory and genetic inputs combine to 
control cdG production, and hence SCV evolution, in the 
CF lung.42
The yfiBNR signaling operon12 represents a further, well-
characterized genetic target for clinically-arising SCVs. YfiN 
is a membrane-bound DGC whose activity is normally allos-
terically repressed by the soluble periplasmic repressor YfiR. 
Release of YfiR repression, either through a loss-of-function 
mutation in yfiR or an “escape” mutation in yfiN, leads to 
DGC activation, cdG overproduction, and SCV formation 
under laboratory conditions.12,26 As with wspF and fleQ, acti-
vating mutations arise in the yfi locus (in both yfiR and yfiN) 
during long-term CF lung infections, driving SCV formation 
in vivo (Figure 5).26 Interestingly, further examination of 
the CF isolates included in this study identified mutational 
“scars” in the yfi genes of two independent clinical CF lines. 
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These strains contained both activating and loss-of-function 
mutations in the yfiN DGC gene, supporting the idea that 
YfiN activity is under both positive and negative selection 
in vivo, with Yfi-SCVs acting as an environmental pool for 
the generation of new smooth morphotypes in the complex 
and heterogeneous fitness landscape of the CF lung.26
Another class of mutations associated with the clinical 
emergence of the SCV phenotype are those in mutS and 
other mismatch repair genes. These hypermutatable strains 
arise with high frequency in the course of chronic CF lung 
infection.37,79 Mena et al35 showed that a P. aeruginosa 
mismatch-repair mutation increased the long-term persis-
tence of oropharyngeal colonization in CF mice, and that 
SCV mutants readily emerged over time in this background. 
The phenomenon of SCV morphotypes arising in hypermu-
tatable P. aeruginosa backgrounds has been independently 
observed for another ∆mutS mutant strain,80 which was also 
shown to produce a large number of mutations in the lasR 
quorum sensing locus.36 The work of Mena et al35 strongly 
suggests that mismatch repair mutants are selected in chronic 
P. aeruginosa lungs due to their increased persistence. As 
a possible explanation for this, hypermutatable strains have 
been linked to the RsmA signaling network in Erwinia 
carotovora,81 placing RsmA downstream of mutS and sug-
gesting that the persistence of these strains may result (at least 
in part) from reduced levels of RsmA (Figure 5). Another 
possibility is simply that the increased rate of mutation in 
these strains facilitates the emergence of mutations in the 
Gac/Rsm or cdG signaling pathways. Genetic adaptation to 
the CF lung has been shown to be catalyzed by the initial 
acquisition of mismatch repair mutations, with subsequent 
mutations arising much more rapidly than in nonmutator 
lines.82 Mutants in the cdG signaling genes fleQ and wspF 
were identified in this study, although the isolate library 
used was the same as described in the earlier work of Smith 
et al,6 where the wspF and fleQ mutations were initially 
identified.
Large-scale DNA inversions have also been associated 
with the generation of morphological diversity, and hence 
potentially SCV generation, in the lung environment. In a 
study of CF lung isolates, Römling et al83 showed that 50% of 
tested P. aeruginosa genomes contained large chromosomal 
inversions. These inversions were exclusively detected in CF 
lung isolates, suggesting that they are selected during adapta-
tion to chronic lung infection.83 Chromosomal inversions have 
been linked to the mobile element IS6100 and are proposed 
to represent a source of phenotypic variation,84 similar to that 
emerging from the loss of mismatch repair described above.80 
Furthermore, reversible genomic inversion has been shown 
to induce an SCV phenotype in S. aureus.85
Recently, the advent of next-generation sequencing has 
enabled the molecular basis of SCV formation to be exam-
ined much more closely. The complete genome sequences 
of at least two clinically-evolved SCVs have been published, 
allowing candidate causal mutations for generation of the 
SCV phenotype to be investigated. For SCV20265,86 the 
mutational routes to SCV are known,42 while for the urethral 
catheter SCV MH27,87 the underlying genetics of the SCV 
phenotype has yet to be established. As sequencing technol-
ogy continues to improve and becomes ever more accessible, 
it is likely that the coming years will see a much more com-
plete examination of the mutational and regulatory routes to 
SCV generation in the CF lung environment.
Summary
P. aeruginosa SCVs are frequently isolated from the lungs 
of CF patients. The appearance of these distinctive, small, 
autoaggregative colonies strongly correlates with both dete-
riorating lung function and associated poor clinical prognosis. 
Whether this connection is causal or simply correlative is not 
yet clear. Nonetheless, the importance of the SCV phenotype 
in persistence of P. aeruginosa infection is beyond doubt, 
with SCVs conferring both increased antibiotic tolerance and 
resistance to immune phagocytosis. Hopefully, an increased 
awareness of the importance of SCVs in chronic CF infec-
tion, alongside recent improvements in both diagnostic and 
analytical tools, will allow us to make headway in the treat-
ment of these unusual morphotypes.
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